A risk-benefit assessment of octreotide in the treatment of acromegaly

Drug Safety

Volumn 17, Issue 5, 1997, Pages 317-324

  Van der Lely, Aart Jan ^a,b   De Herder, Wouter W ^a   Lamberts, Steven W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ACROMEGALY; DIARRHEA; GALLSTONE; GASTRITIS; HAIR LOSS; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0030668649     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717050-00004     Document Type: Review

References (94)

1. Cushing H. Partial hypophysectomy for acromegaly. Ann Surg 1906; 1: 1002-7
2. Flogstad AK, Halse J. Cirass P. et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinal Metab 1994; 79: 461-5
3. Chiodini PG, Attanasio K, Cozzi R, et al. CV 205-502 in acromcgaly. Acta Endocrinol (Copenh) 1993; 128: 389-93
4. Ezzat S, Snyder PJ, Young WF, et al. Octrcotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med 1992; 117: 711-8
5. Lamberts SW, Reubi JC, Krenning EP. Somatostatin analogs in the treatment of acromegaly. Endocrinol Metab Clin North Am 1992; 21: 737-52
6. Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the someatostatin analogue SMS 201-995. N Engl J Med 1985; 313: 1576-80
7. Lamberts SW. van der Lely AJ, de Herder WW, et al. Oetrcotide. N Engl J Med 1996; 334: 246-54
8. Caron P, Cogne M, Gusthiot-Joudet B, et al. Intramuseular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 1995; 132: 320-5
9. Acromegaly Therapy Consensus Development Panel. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 1994; 97: 468-73
10. Marek J, Hana V, Krsek M, et al. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanrcotide. Eur J Endocrinol 1994; 131: 20-6
11. Wagenaar AH, Harris AG, van der Lely AJ, et al. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol (Copenb) 1991; 125: 637-42
12. Fredstorp L, Kutx K, Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clin Endocrinol Oxf 1994; 41: 103-8
13. Bengtsson BA, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Stand 1988; 223: 327-35
14. Klijn JG, Lamberts SW, de Jong FH, et al. Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellur extension in acromegalic patients. Acta Endocrinol (Copenb) 1980; 95: 289-97
15. van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol Oxf 1992; 37: 181-5
16. de Herder WW. Uittirlinden P, van der Lely AJ, et al. Octreotide, but not bromocriptine, increases circulating insulin-like grouth factor binding protein 1 levels in acromegaly. Eur J Endocrinol 1995; 133: 195-9
17. de Herder WW, van der Lely AJ, Janssen JA, et al. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol Oxf 1995; 43: 501-5
18. Ezzat S, Ren SG, Braunstein GD, et al. Octrcotidc stimulates insulin-like growth fuctor-binding protein-1: a potential piluitary-independent mechanism for drug action. J Clin Endocrinol Metab 1992; 75: 1459-63
19. Orskov H, Wolthers T, Crofte T, et al. Somatostatin-stimulated insulin-like growth factor binding protein-1 release is abolished by hyperinsulinemia. J Clin Endocrinol Metab 1994; 78: 138-40
20. Ren SG, Ezzat S, Mclmed S, et al. Somatostatin analog induces insulin-like growth factor binding protein-1 (GFBP-I) expression in human hepatoma cells. Endocrinology 1992; 131: 2479-81
21. Wolthers T, Grofte T, Flyvbjerg A, et al. Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analog. J Clin Endocrinol Metab 1994; 78: 141-4
22. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from at pituitary in vitro. Endocrinology 1968; 83: 783-90
23. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreaetive pituitary growth hormone. Science 1973; 179: 77-9
24. Reichlin S, Sumatostatin (First of two parts). N Engl J Med 1983; 309: 1495-501
25. Reichlin S, Somutostatin (Second of two parts). N Engl J Med 1983; 309: 1556-63
26. Marks N, Stern F, Benuek M. Correlation between biological potency and biodegradation of a somatostutin analogue. Nature 1976; 261: 511-2
27. Marks N, Stem F. Inactivation of somatostatin (GH-RIH) and its an analogs by crude and partially purified rat brain extracts. FEBS Lett 1975; 55: 220-4
28. Lamberts SW, Oosterom R, Neufeld M, et al. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60: 1161-5
29. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 4511-82
30. Di Leo A, Bajetta E, Ferruri L, et al. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma. Cancer 1996; 78: 35-42
31. Di Leo A, Ferrari L, Bajetta E, et al. Biological and clinical evaluation of lanreotide (BIM 2301). a somatostatin analogue, in the treatment of advanced breast cancer: a pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology. Breast Cancer Res Treat 1995; 34: 237-44
32. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994; 38: 213-9
33. Burthomeuf C, Pourrat H, Pourrat A, et al. Stabilization of Octastatin, a somatostatin analogue: comparative accelerated stability studies of two formulations for freeze-dried products. Pharm Acta Helv 1996; 71: 161-6
34. Pinski J, Schally AV, Halmos G, et al. Somatostatlin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer 1996; 65: 870-4
35. Yamada Y, Reisine T, Law SF, et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cycluse. Mol Endocrinol 1992; 6: 2136-42
36. Patel YC, Greenwood MT, Panetta R, et al. The somatostatin receptor family. Life Sci 1995; 57: 1249-65
37. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octrcotide therapy of acromegaly: results of a mullicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995; 80: 2768-75 39.
38. Redfern JS, Fortuner WJ, II. Octreutide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995; 90: 1042-52
39. Stolk MF, van Erpecum KJ, Koppeschaar HP, et al. Effect of octrcotide on fasting gall bladder emptying, antroduodenal motilily, and motilin release in acromegaly. Gut 1995; 36: 755-60
40. Erlinger S, Chanson P, Dumont M, et al. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly: a prospective study. Dig Dis Sci 1994; 39: 2384-8
41. Hussaini SH, Murphy CM, Kennedy C, et al. The role of bile composition and physical chemistry in the pathogencsis of octrcotide-associated gallbladder stones. Gastroenterology 1994; 107: 1503-13
42. Montini M, Gianola D, Pagani MD, et al. Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol Oxf 1994; 40: 401-6
43. Shi YF, Zhu XF, Harris AG, et al. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients. Acta Endocrinol (Copenh) 1993; 129: 207-12
44. Schmidt K, Leuschner M, Harris AG, et al. Gallstones in acromegalic patients undergoing different treatment regimens. Clin Investig 1992; 70: 556-9
45. Flogstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995; 80: 3601-7
46. McKnight JA, McCancc DR, Sheridan B, et al. Four years' treatment of resistant acromegaly with octreotide. Eur J Endocrinol 1995; 132: 429-32
47. Nakauchi Y, Kumon Y, Yamasaki H, et al. Scalp hair loss caused by octreotide in a patient with acromegaly: a case report. Endocr J 1995; 42: 385-9
48. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994; 130: 581-6
49. Landolt AM, Schmid J, Wimpfheimer C, et al. Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly. N Engl J Med 1989; 320: 671-2
50. Montini M, Pagani G, Gianola D. et al. Acromegaly and primary amenorrhea: ovulation and pregnancy induced by SMS 201-995 and bromocriptine. J Endocrinol Invest 1990; 13: 193
51. Daluiso S, Daluiso BD. Acute pancreatitis in pregnancy treated with somatostatin: a case report. Minerva Chir 1994; 49: 733-6
52. Haraguchi K, Ohtaka M, Takazawa K, et al. Desensitization to somatotatin analogue (Octreotide) observed in a patient with acromegaly. Endoer J 1995; 42: 295-300
53. Frohman LA. Acromegaly: what constitutes optimal therapy? J Clin Endocrinol Metab 1996; 81: 443-5
54. Melmed S: Medical management of acromegaly - what and when? Acta Endocrinol (Copenh) 1993; 129 Suppl. 1: 13-7
55. Puchner MJ, Knappe UJ, Ludecke DK. Pituitary surgery in elderly patients with acromegaly. Neurosurgery 1995; 36: 677-83; discussion 683-4
56. Melmed S, Ho K, Klibanski A, et al. Clinical review 75: recent advances in pathogenesis. diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995; 80: 3395-402
57. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly: clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73: 233-40
58. Movsas B, Movsas TZ, Steinberg SM, et al. Long-term visual changes following pituitary irradiation. Int J Radiat Oncol Biol Phys 1995; 33: 599-605
59. Toogood AA, Ryder WD, Beardwell CG, et al. The evolution of radiation-induced growth hormone deficiency in adults is determined by the basetine growth hormone status. Clin Endocrinol Oxf 1995; 43: 97-103
60. Bliss P, Kerr GR, Gregor A. Incidence of second brain tumours after pituitary irradiation in Edinburgh 1962-1990. Clin Oncol (R Coll Radiol) 1994; 6: 361-3
61. Goldsmith BJ, Shrieve D, Loeffler JS. High efficacy without visual damage: the current status of pituitary radiotherapy. Int J Radial Oncol Biol Phys 1995; 33: 765-7
62. Jaquet P. CV 205-502: a more effective dopamine agonist in the treatment of acromegaly? Eur J Endocrinol 1995; 132: 557-8
63. Svoboda T, Kotzmann H, Clodi M, et al. The non ergot D2-dopamine agonist CV 205-502 decreases growth hormone concentrations in acromegalic patients. Endocr Res 1994; 20: 59-63
64. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992; 21:713-35
65. Oppizzi G, Liuzzi A, Chiodini P, et al. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. J Clin Endocrinol Metab 1984; 58: 988-92
66. Ho KY, Thorner MO. Therapeutic applications of bromocriptinc in endocrine and neurological diseases. Drugs 1988; 36: 67-82
67. Rosenberg JM. Octreotide: a synthetic analog of somatostatin. Drug Intell Clin Pharm 1988; 22: 748-54
68. Katz MD, Entlad BL. Octreotide, a new somatostatin analogue. Clin Pharm 1989; 8: 255-73
69. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptidc secretion. Drugs 1989; 38: 658-702
70. Ceda GP, Hoffman AR, Silverberg CD, et al. Regulation of growth hormone release from cultured human pituitary adenomas by somatomedins and insulin. J Clin Endocrinol Metab 1985; 60: 1204-9
71. Chanson P, Timsit J, Harris AC. Clinical pharmacokinetics of octreotide: therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993; 25: 375-91
72. Lamberts SW, Uitterlinden P, del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 1987; 65: 703-10
73. Krishna AY, Phillips LS. Management of acromegaly: a review. Am J Med Sci 1994; 308: 370-5
74. Jaffe CA, Barkan AL. Acromegaly: recognition and treatment. Drugs 1994; 47: 425-45
75. Thissen JP, Ketelslegers JM, Maiter D. Use of insulin-like growth facior-I (IGF-I) and IGF-binding protcin-3 in the diagnosis of acromegaly and growth hormone deficiency in adults. Growth Regul 1996; 6: 222-9
76. Grinspoon S, Clemmons D, Swearingen B, et al. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995; 80: 927-32
77. Ho KY, Weissberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol Oxf 1994; 41: 75-83
78. Barkan AL, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somaloslatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67: 1040-8
79. Ezzat S, Kontogeorgos G, Redelmeier DA, et al. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995; 133: 686-90
80. Stevenacrt A, Deckers A. Presurgical octreotide treatment in acrornegaly. Acta Endocrinol (Copenh) 1993; 129 Suppl. 1: 18-20
81. Stevenaert A, Harris AC, Kovacs K, et al. Presurgical octreotide treatment in acromegaly. Metabolism 1992; 41: 51-8
82. Johnson MR, Chowdrey HS, Thomas F, et al. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 1994; 130: 229-34
83. Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acrontegaly. J Clin Endocrinol Metab 1993; 76: 721-7
84. Giusti M, Gussoni G, Cuttica CMm et al. Effectiveness and toleribilily of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab 1996; 81: 2089-124
85. Hofland LJ, Lamberts SW. Somatostatin receptors and disease: role of receptor subtypes. Baillieres Clin Endocrinol Metab 1996; 10: 163-76
86. Greenman Y, Melmed S. Heterogeneous expression of two sumatustalin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 1994; 78: 398-403
87. ReisineT, Bell GI. Molecular properties of somatostatin receptors. Neuroscience 1995; 67: 777-90
88. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-8
89. Miller GM, Alexander JM, Bikkal HA, et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995; 80: 1386-92
90. Raulf F, Perez J, Hoyer D, et al. Differential expression of five somatostatin receptor subtypes. SSTRI-5, in the CNS and peripheral tissue. Digestion 1994; SS Suppl. 3: 46-53
91. Bruns C, Weckbecker G, Raulf F, et al. Molecular pharmacology of somatostalin-receplor subtypes. Ann N Y Acad Sci 1994; 733: 138-46
92. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93: 1321-5
93. Liebow C, Reilly C, Serrano M, et al. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989; 86: 2003-7
94. Buscail L, Delesque N, Esteve JP, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994; 91: 2315-9